|
KMID : 0545120020120050787
|
|
Journal of Microbiology and Biotechnology
2002 Volume.12 No. 5 p.787 ~ p.792
|
|
|
Development of a Quadrivalent Combined DTaP-HepB Vaccine with e Low Toxicity and a Stable HBsAg Immunogenicity
|
|
BAE, CHEON-SOON/BAE, CHEON-SOON
PARK, KYUNG-NAM/AHN, SANG-JEOM/KIM, JONG-SU/HUR, BYUNG-KI/PARK, KYUNG-NAM/AHN, SANG-JEOM/KIM, JONG-SU/HUR, BYUNG-KI
|
|
|
Abstract
|
|
|
|
When developing a combined DTaP-HepB vaccine, toxicity and HBsAg immunogenicity are both important considerations. Thus, for a combined DTaP-HepB vaccine with a low toxicity, the effect of the DTaP content and Al(OH)_3 gel concentration on the vaccine toxicity was investigated. Within the rage studied, the higher the concentrations, the higher the vaccine toxicity. The importance of the tetanus toxoid content in the combined DTaP-HepB vaccine was also revealed. A higher concentration of the tetanus toxoid was found tk have a negative effect on the stability of the HBsAg immunogenicity in the combined vaccine. Accordingly, considering the factors affecting toxicity and HBsAg immunogencity, a novel DTaP-HepB vaccine (30 Lf/ml of diphtheria toxoid, 5 Lf/ml of tetanus toxoid, 10 ㎍ PN/ml of acellular pertussis, 24 ㎍/ml of HBsAg, and 500 ㎍ Al/ml of Al(OH)_3 gel) was developed. It has a low toxicity and a stable HBsAg immunorencity and also satisfies the potency criteria of K-FDA for a combined DTaP vaccine.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|